Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinchcombe

Showing results (491-500 of 575) with videos related to

Pageof 58
Sort By:
International Journal of Radiation Oncology, Biology, Physics|May 5, 2026
Brief Report: Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: CALGB 30610 (Alliance) / RTOG 0538Jeffrey A Bogart, Xiaofei Wang, Gregory Masters, et al.
Plos Genetics|February 16, 2019
Parental legacy, demography, and admixture influenced the evolution of the two subgenomes of the tetraploid Capsella bursa-pastoris (Brassicaceae)Dmytro Kryvokhyzha, Adriana Salcedo, Mimmi C Eriksson, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2010
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patientsJanine M Davies, Nirav S Dhruva, Christine M Walko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2017
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 GyKyle Wang, Michael J Eblan, Allison M Deal, et al.
Lung Cancer (Amsterdam, Netherlands)|November 28, 2022
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort StudyMonica H Bodd, Susan C Locke, Steve P Wolf, et al.
JTO Clinical and Research Reports|September 30, 2021
Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLCThomas A Hensing, Xiaofei Wang, Thomas E Stinchcombe, et al.
Immunity|May 21, 2015
Actin depletion initiates events leading to granule secretion at the immunological synapseAlex T Ritter, Yukako Asano, Jane C Stinchcombe, et al.
Clinical Lung Cancer|May 25, 2022
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancerSteven E Schild, Xiaofei Wang, Christine M Bestvina, et al.
American Journal of Clinical Oncology|September 3, 2014
ACR appropriateness Criteria® early-stage non-small-cell lung cancerGregory M M Videtic, Joe Yujiao Chang, Indrin J Chetty, et al.
JAMA Oncology|August 9, 2019
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical TrialThomas E Stinchcombe, Pasi A Jänne, Xiaofei Wang, et al.
Pageof 58

Showing results (491-500 of 575) with videos related to

Sort By:
Pageof 58
International Journal of Radiation Oncology, Biology, Physics|May 5, 2026
Brief Report: Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: CALGB 30610 (Alliance) / RTOG 0538Jeffrey A Bogart, Xiaofei Wang, Gregory Masters, et al.
Plos Genetics|February 16, 2019
Parental legacy, demography, and admixture influenced the evolution of the two subgenomes of the tetraploid Capsella bursa-pastoris (Brassicaceae)Dmytro Kryvokhyzha, Adriana Salcedo, Mimmi C Eriksson, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2010
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patientsJanine M Davies, Nirav S Dhruva, Christine M Walko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2017
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 GyKyle Wang, Michael J Eblan, Allison M Deal, et al.
Lung Cancer (Amsterdam, Netherlands)|November 28, 2022
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort StudyMonica H Bodd, Susan C Locke, Steve P Wolf, et al.
JTO Clinical and Research Reports|September 30, 2021
Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLCThomas A Hensing, Xiaofei Wang, Thomas E Stinchcombe, et al.
Immunity|May 21, 2015
Actin depletion initiates events leading to granule secretion at the immunological synapseAlex T Ritter, Yukako Asano, Jane C Stinchcombe, et al.
Clinical Lung Cancer|May 25, 2022
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancerSteven E Schild, Xiaofei Wang, Christine M Bestvina, et al.
American Journal of Clinical Oncology|September 3, 2014
ACR appropriateness Criteria® early-stage non-small-cell lung cancerGregory M M Videtic, Joe Yujiao Chang, Indrin J Chetty, et al.
JAMA Oncology|August 9, 2019
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical TrialThomas E Stinchcombe, Pasi A Jänne, Xiaofei Wang, et al.
Pageof 58